Manali Kamdar, MD

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Treatment with CAR T-cell therapy for LBCL, like liso-cel, can impact QOL based on restrictions made on the label.

The 48-month OS rate for the TRANSFORM plus long-term follow-up study was 61.5% for patients with R/R LBCL.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.